Haemate P

Haemate P is a solution for injection containing human coagulation factor VIII and von Willebrand factor. It is supplied as a sterile intravenous concentrate, marketed in the European Union, and prescribed for patients with hemophilia A or von Willebrand disease. The product provides replacement of deficient clotting factors to support normal hemostasis and to manage bleeding episodes under medical supervision and according to clinical guidelines.

Haemate P is indicated for the treatment and prophylaxis of bleeding in individuals with specific clotting factor deficiencies.

- Replacement therapy for patients with hemophilia A (factor VIII deficiency). - Management of acute bleeding episodes in von Willebrand disease. - Surgical or invasive procedure support to prevent peri‑operative hemorrhage in eligible patients. - Long‑term prophylactic regimens to reduce frequency of spontaneous bleeds. - Use in combination with other hemostatic agents when clinically appropriate.

Adverse reactions reported with Haemate P are generally consistent with other plasma‑derived factor concentrates.

Common: - Headache or mild fever. - Injection site erythema, swelling, or discomfort. - Transient increase in liver enzymes. - Nausea or mild abdominal discomfort. - Fatigue or malaise.

Serious: - Development of inhibitors (antibodies) against factor VIII. - Anaphylactic or severe allergic reactions. - Thromboembolic events such as deep‑vein thrombosis. - Transmission of infectious agents (viral or prion) despite screening. - Severe hypotension or shock following infusion. - Renal impairment or hemolysis.

When prescribing Haemate P, clinicians should consider several precautionary measures to ensure patient safety.

- Assess for a history of inhibitors to factor VIII before initiating therapy. - Evaluate for known hypersensitivity to any component of the product. - Monitor for signs of infection or viral transmission, especially in immunocompromised patients. - Use the lowest effective dose and adjust based on clinical response and laboratory parameters. - Avoid rapid infusion rates that may increase the risk of adverse reactions. - Conduct regular screening for thrombotic complications during prolonged treatment.

Haemate P may interact with other medications that affect hemostasis or immune response.

Avoid: - Concomitant use of high‑dose pro‑coagulant agents (e.g., activated factor VII) without specialist guidance. - Simultaneous administration of other plasma‑derived clotting factor concentrates unless clinically indicated.

Use with caution: - Antifibrinolytic agents such as tranexamic acid, which may increase clot stability. - Immunosuppressive drugs that could alter inhibitor development risk. - Vaccines administered shortly before or after infusion, to avoid overlapping immune activation. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) that may exacerbate bleeding tendencies.